13 results about "Neuromyelitis optica" patented technology

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

The invention discloses a method for analyzing serum differential expression protein characteristics of an AQP4-IgG positive NMOSD patient, and relates to the technical field of differential expression protein characteristic analysis, and the method comprises the following steps: S1, collecting a serum sample of a to-be-detected subject; s2, carrying out protein detection on the serum sample to obtain expression level data of at least one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8, wherein the expression level data is one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8; s3, carrying out comparative analysis on the expression level of the serum protein and a pre-established AQP4-IgG positive NMOSD serum protein expression characteristic reference standard; according to the method for auxiliary diagnosis of the AQP4-IgG positive neuromyelitis optica pedigree disease provided by the invention, a judgment mode capable of reflecting molecular characteristics of the AQP4-IgG positive neuromyelitis optica pedigree disease is constructed by carrying out conjoint analysis on various serum protein expression characteristics related to immunoregulation, inflammatory response, complement activation and metabolism; therefore, the problem of insufficient detection stability of a single biomarker is avoided.

The present invention pertains to the anti-inflammatory therapeutic effect of xantohumol in spinal cord injury (SCI). The continuous administration of xanthohumol for 1-8 weeks to SCI rats resulted in improved results in 4 clinical tests used and in lowering and faster elimination of macrophages from the SCI lesion. Since the infiltration of the SCI lesion by numerous phagocytic macrophages indicates a severe destructive inflammation of extraordinary longevity, administration of xanthohumol is neuroprotective and resulted in a better and faster recovery of the locomotor function and the strength and sensory function in the hind limbs, in a shorter period of paralysis of the urinary bladder and in the recovery of the body weight lost due to the SCI surgery. Since the traumatic brain injury (TBI) involving the white matter, and stroke involving the white matter initiate the severe destructive inflammation as in the SCI, the administration of xanthohumol is expected to be anti-inflammatory and neuroprotective in both brain diseases. Since neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia and Parkinson's disease, immune mediated neuroinflammation including multiple sclerosis and neuromyelitis optica and cerebrospinal infections have inflammatory pathogenesis involving microgliosis and infiltration by macrophages, the administration of xanthohumol is expected to result in therapeutic inhibition of progression of all above diseases as well as of related neurodegenerative, immune mediated and infectious diseases of the brain and of the spinal cord.

An N-(4-trifluoromethyl)-2-cyanocrotonamide compound, a preparation method therefor, and a pharmaceutical composition and use thereof. The compound of the present invention has a more significant treatment effect on central nervous system diseases such as multiple sclerosis and neuromyelitis optica.

The present invention relates to a biomarker for diagnosing neuromyelitis optica and its use. Specifically, the present invention relates to a biomarker composition for diagnosing neuromyelitis optica comprising one or more genes selected from the group consisting of Plac8 (placenta-specific 8), Klra2 (killer cell lectin-like receptor, subfamily A, member 2) and Mcoln2 (mucolipin 2) or a protein expressed from said genes; a composition for diagnosing neuromyelitis optica comprising a substance for measuring the mRNA level of said genes or the protein level thereof; a diagnostic kit for neuromyelitis optica comprising said composition; and a method for providing information for predicting and diagnosing neuromyelitis optica.

Disclosed is an application of sBCMA as a biomarker in cerebrospinal fluid in diagnosis and monitoring of antibody-mediated central nervous system autoimmune diseases. Taking NMOSD as an example, the level of sBCMA in cerebrospinal fluid of NMOSD patients is significantly higher than that of control subjects matched for age and gender, and there is a positive correlation between the level of sBCMA in cerebrospinal fluid and a nerve injury-related index NFL, a blood-cerebrospinal fluid barrier breakdown-related index QAlb, or a neuroinflammation-related index sTREM2 in cerebrospinal fluid of NMOSD patients. This indicates that the level of sBCMA in cerebrospinal fluid can be used as a biomarker for the diagnosis of antibody-mediated central nervous system autoimmune diseases such as NMOSD and the evaluation of the severity of nerve injuries, the degree of damage to blood-cerebrospinal fluid barrier, and the level of neuroinflammation in patients.

This invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease, and MOG antibody-positive neuromyelitis optica. More specifically, this invention relates to recombinant polypeptides comprising a peptide antigen and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods for preparing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use for the treatment of multiple sclerosis (MS), MOG antibody disease, and MOG antibody-positive neuromyelitis optica.

Provided herein are compositions and methods for treating neuroinflammatory diseases and conditions, the neuroinflammatory diseases and conditions include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), optic neuromyelitis (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), vascular dementia (VAD), anti-oligodendroglia glycoprotein antibody disease (MOGAD), and the like. Transverse myelitis (TM), autoimmune encephalitis (AE), acute disseminated encephalomyelitis (ADEM), chronic meningitis (CM), central nervous system (CNS) vasculitis, hashimoto encephalitis (HE), neurosarcoidosis (NS), multi-system atrophy (MSA), migraine, chemotherapy-induced pain or dementia-related pain.

In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

The application belongs to the technical field of medicines, and specifically discloses a novel 5-6-7-5 ring system beta acid compound, a preparation method thereof and application of the compound in resisting neural inflammation. The novel 5-6-7-5 ring system beta acid compound is first separated from nature, has good anti-neural inflammation effect, and can be used for developing medicines for treating neural inflammation related diseases, including but not limited to depression, Alzheimer's disease, Parkinson's syndrome, Huntington's disease, opticospinal neuritis and peripheral neuritis.

In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

The present disclosure in various aspects provides methods for making pharmaceutical compositions for treating neurodegenerative diseases (e.g., demyelinating diseases), such as but not limited to multiple sclerosis, neuromyelitis optica, and transverse myelitis. The pharmaceutical compositions impact specific antibody-mediated processes involved in the biology of neurodegenerative disease. In certain aspects, the disclosure provides pharmaceutical compositions for treating neurodegenerative disease, which are based on inhibiting the action of pathologic antibodies, or alternatively providing antibodies to stimulate neuroprotection or repair processes.

Compositions and methods for treating neuroinflammatory diseases and conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (AES), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), neuromyelitis optica (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), vascular dementia (VAD), anti-myelin oligodendrocyte glycoprotein antibody disease (MOGAD), transverse myelitis (TM), autoimmune encephalitis (AE), acute disseminated encephalomyelitis (ADEM), chronic meningitis (CM), central nervous system (CNS) vasculitis, Hashimoto's encephalitis (HE), neurosarcoidosis (NS), multiple system atrophy (MSA), migraine, chemotherapy-induced pain, or dementia-related pain, are provided herein.